pasritamig, KLK2 T-cell engager, bispecific antibody prostate cancer, Phase I trial results, mCRPC immunotherapy, Pasritamig Safety and Efficacy Data from Metastatic CRPC Phase I Study with Capucine ...

PDIGREE phase III adaptive, enrolled 1000+ metastatic kidney cancer patients across 500+ sites, ASCO 2025 results and innovative treatment strategies, PDIGREE Trial Tests Adaptive Immunotherapy ...

Trimodality therapy (TMT), consisting of maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy, has emerged as a bladder-sparing alternative to radical ...

Andrea Miyahira hosts Marina Sharifi about a multiomic profiling study of metastatic castration-resistant prostate cancer using circulating tumor cells, ctDNA, and RNA sequencing.

At the 2025 UCSF-UCLA PSMA Conference, Matthias Eiber compares PSMA-617 and PSMA-I&T radiopharmaceuticals. He notes both agents share binding motifs but differ in chelator properties and linker ...

ASCO 2025, Non–muscle-Invasive Bladder Cancer (NMIBC), Intravesical Sacituzumab Tirumotecan, Intermediate-Risk Non–muscle-Invasive Bladder Cancer, TroFuse-027 Study, Trophoblast cell-surface antigen 2 ...

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC CG Oncology, Inc.

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

Erectile Dysfunction - Read the latest Erectile Dysfunction research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Looking for the latest abstracts on prostate cancer treatment and research? We've got you covered and then some.

Bladder Cancer - Read the latest Bladder Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

AUA 2025 Tokai Urologic Oncology Research Study (TOURS) database study, tyrosine kinase inhibitors (TKIs), immunotherapy (IO), advanced renal cell carcinoma (RCC).